Alcon third-quarter sales rise 5% to $2.7bn; Neurotech acquisition announced
The eye-care company reported nine-month sales of $8.2bn, with dry eye products and surgical equipment launches driving growth, and highlighted its planned purchase of Neurotech Pharmaceuticals.
Alcon reported net sales of $2.7bn for the third quarter of 2026, up 5%, in results published on 10 November 2026. For the first nine months of the year, sales reached $8.2bn, a 7% increase.
The company attributed growth to its Vision Care business, including dry eye products such as Tryptyr and Systane, and to launches of surgical equipment. Core diluted earnings per share were $0.91, up 15%.
Alcon also pointed to its recently announced acquisition of Neurotech Pharmaceuticals, which it said is intended to strengthen its retinal disease portfolio. The summary available does not set out the terms of the deal or the products involved.
The headline on the release also refers to competition in the US market for intraocular lenses (IOLs), which new products helped offset. No further detail on that competition was available in the material reviewed.
Why it matters
- Market-access teams in ophthalmology should note the continued commercial weight of dry eye products, including Tryptyr and Systane, in Alcon's growth.
- The planned Neurotech Pharmaceuticals acquisition signals Alcon's intent to build out its retinal disease portfolio; regulatory teams may wish to watch for deal terms and product details.
- Competitive pressure in US intraocular lenses is cited alongside the results, relevant to those tracking the surgical device segment.
Company's press release (SEC filing): Alcon Inc ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
MacroGenics reports $288M cash and 2028 runway, putting B7-H3 ADC MGC026 in head and neck cancer first
Xenetic reports Q3 loss, advances all-stock Santersus deal and doses first DNase I CAR-T patient
Longeveron seeks FDA meeting after ELPIS II miss and starts strategic alternatives review
Silence Therapeutics narrows Q3 loss as Merck KGaA deal and divesiran data take centre stage
Theriva Sells SYN-004 Antibiotic-Enzyme Assets to Biossil Labs for $350,000 Upfront
